NewLink Genetics Corporation
NEWLINK GENETICS CORP (Form: 8-K, Received: 03/01/2017 17:30:40)

Washington, D.C. 20549

Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2017

NewLink Genetics Corporation
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(IRS Employer
of incorporation)
File Number)
Identification No.)
2503 South Loop Drive
Ames, IA
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (515) 296-5555
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 - Other Events

Item 8.01.    Other Events.
On March 1, 2017, NewLink Genetics Corporation (the "Company") issued a press release titled "NewLink Genetics Announces Presentation of Two Abstracts at AACR."
The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Section 9 - Financial Statements and Exhibits
Item 9.01.              Financial Statements and Exhibits.
(d)  Exhibits.
Exhibit Number
Press Release, dated March 1, 2017, entitled “NewLink Genetics Announces Presentation of Two Abstracts at AACR”

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated:    March 1, 2017

NewLink Genetics Corporation
/s/ John B. Henneman III
  John B. Henneman III
  Chief Financial Officer


Exhibit Number
Press Release, dated March 1, 2017, entitled “NewLink Genetics Announces Presentation of Two Abstracts at AACR”

Exhibit 99.1

NewLink Genetics Announces Presentation of Two Abstracts at AACR

Interim Phase 2 Clinical Results of IDO Pathway Inhibitor, Indoximod Selected for an Oral Presentation During the Clinical Trial Plenary Session

AMES, Iowa, March 1, 2017 - NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported that two abstracts on the company’s indoximod program will be presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C.
Clinical Trials Plenary Session: Abstract CT117 - Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma , to be presented during the Novel Immuno-Oncology Agent Clinical Trials session, Tuesday April 4, 2017 10:30 a.m. - 12:45 p.m. ET.

Poster Session: Abstract 4076 - A novel prodrug of indoximod with enhanced pharmacokinetic properties, to be presented during poster session PO.ET05.01 - Mechanistic Understanding of Novel Anticancer Therapies, April 4, 2017 1 p.m. - 5 p.m. ET.

The complete text of Clinical Plenary Session abstracts that have not been selected for the press program will be posted online at 4:30 p.m. ET on Friday, March 31. The text of clinical trials abstracts that have been selected for inclusion in the press program will not be posted online until the date and time of presentation.
"We are honored to have been selected by the AACR review committee for the Clinical Trials Plenary Session at the upcoming AACR meeting,” said Nicholas Vahanian, M.D., President and Chief Medical Officer. “We look forward to sharing the data from both of these abstracts.”

About NewLink Genetics Corporation
NewLink Genetics is a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' product candidates are designed to harness multiple components of the immune system to combat cancer.  For more information, please visit

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties.  All statements, other than statements of historical fact, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these

Exhibit 99.1

identifying words.  These forward-looking statements include, among others, statements about results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; and any other statements other than statements of historical fact.  Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics' Annual Report on Form 10-K for the year ended December 31, 2015 and other reports filed with the U.S. Securities and Exchange Commission (SEC).  The forward-looking statements in this press release represent NewLink's views as of the date of this press release. NewLink anticipates that subsequent events and developments will cause its views to change.  However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.  You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.

Beth Kurth
617-374-8800, ext. 106

Alison Chen
617-374-8800, ext. 104